Acar O.Ayhan M.Demir B.Ekinci F.Aytac A.Erdogan A.P.2024-07-222024-07-2220231022386Xhttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11732Objective: To investigate the effect of the haemoglobin, albumin, lymphocyte, and platelet (HALP) score (Haemoglobin, Albumin, Lymphocyte, Platelet count) on survival as a new prognostic factor in metastatic bladder cancer. Study Design: Descriptive study. Place and Duration of the Study: Department of Medical Oncology, Celal Bayar University, Manisa, Turkey, and Adnan Menderes University, Aydin, Turkey, from 2010 to 2020. Methodology: The medical charts of patients with metastatic bladder cancer were reviewed retrospectively. Prognostic value of the HALP score as a marker of overall survival was examined through a receiver operating characteristic (ROC) curve analysis. Results: The cut-off value for the HALP score in the ROC curve analysis was 29. The median overall survival (OS) was 19 months when the HALP score was less than 29, and the median OS was 40 months when the HALP score was 29 or greater, and this finding was statistically significant (p = 0.003). Conclusion: The HALP score is closely related to prognosis in metastatic bladder cancer. A high HALP score is associated with better survival outcomes. © 2023 College of Physicians and Surgeons Pakistan. All rights reserved.EnglishAll Open Access; Gold Open AccessAlbuminsHemoglobinsHumansLymphocytesPrognosisRetrospective StudiesUrinary Bladder Neoplasmsalbuminalkaline phosphatasebilirubinC reactive proteincreatininehemoglobinalbuminhemoglobinadultagedArticlebladder cancerbladder metastasisbody masscancer prognosiscancer survivalclinical featureclinical outcomedistant metastasisfemalefollow uphistopathologyhumanlymphocytemajor clinical studymaleoverall survivalplatelet countprogression free survivalreceiver operating characteristicretrospective studytransurethral resection of the bladderTurkey (republic)bladder tumorpathologyprognosisHALP Score as a New Prognostic Factor for Patients with Metastatic Bladder CancerArticle10.29271/jcpsp.2023.12.1405